Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.
The agent also appeared associated with fewer treatment-related adverse events.
“Pembrolizumab should be considered a new standard of care for these patients,” Thierry André, MD, professor of medical oncology at University Sorbonne and head of the medical oncology department at Hôpital Saint Antoine in Paris, said during a

Source link

Related posts

Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis


Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk


5 esophagus stories you may have missed


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World